NCT07844070Active, not recruiting
A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy
Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
This study aims to assess the real-world patterns of disease modifying therapy (DMT) use before, during, and after pregnancy in women with multiple sclerosis (MS). The study will use a pooled closed claims database containing closed payer medical and pharmacy claims data for patients in the United States (US).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2607 (estimated)
- First submitted
- 21 Sept 2026
- Start date
- 6 Mar 2026
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT07844070
What you commit to
- Study type: Observational
- Planned participants: 2607
- From 6 Mar 2026 to the primary completion date, 30 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Malignancy in pre-conception, pregnancy, or post-delivery periods.
Other
- Pregnancies involving multiples, subject to data availability.
Who the study is looking for
- ≥1 claim with a diagnosis or procedure code for live birth during the patient identification period (index date).
- o Note: For patients with more than one pregnancy in the patient identification period, all eligible pregnancies will be included.
- Female sex recorded on enrollment record overlapping with index date.
- Aged between 18 and 49 years old at index date.
- ≥2 claims with an MS diagnosis (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code G35) ≥30 days apart in the pre-conception or pregnancy periods.
- Continuous healthcare plan enrollment from ≥6 months prior to the conception date to ≥6 months following the index date.
Age in the registry: 18 years to 49 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.